NCT05927649View on ClinicalTrials.gov

A TQTc Study for Omaveloxolone

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

July 11, 2023

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2023

Conditions

Health Adult Subjects

Interventions

DRUG

Omaveloxolone

Omaveloxolone capsules

DRUG

Moxifloxacin

Moxifloxacin capsules

Trial Locations (1)

85283

Celerion, Inc., Tempe

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors

collaborator

Celerion

INDUSTRY

collaborator

Q2 Solutions

INDUSTRY

lead

Biogen

INDUSTRY